| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Inflammatory pathways and autoimmune disease mechanisms. β-Aminoarteether (SM934 free base) is an orally active artemisinin derivative that can be used for inflammation and autoimmune disease research, such as lupus diseases. Artemisinin derivatives are known to have immunomodulatory effects, including the modulation of cytokine production and the inhibition of immune cell activation.
|
|---|---|
| ln Vitro |
After 24 hours of IFN-γ stimulation, β-Aminoarteether (SM934; 10 µM) administration directly increases IL-10 production and decreases IL-12/23p40 production in primary peritoneal macrophages[1]. whilst having no effect on Treg differentiation, decreased Th1 and Th17 polarization[1].
In vitro, β-Aminoarteether is an artemisinin derivative with oral activity. Artemisinin derivatives are known to have immunomodulatory effects, including the modulation of cytokine production and the inhibition of immune cell activation. The compound's activity in autoimmune disease models suggests that it may modulate inflammatory pathways and reduce autoantibody production. |
| ln Vivo |
β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daily; for 3 months) therapy boosts the survival rate of NZB/W F1 mice and considerably delays the advancement of glomerulonephritis. Macrophages from NZB/W F1 mice produce more IL-10 when treated with β-aminoarteether[1].
In vivo, β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases. The compound is orally active, making it suitable for oral administration in animal models. In lupus models, artemisinin derivatives have been shown to reduce disease severity, decrease autoantibody levels, and ameliorate organ damage. |
| Enzyme Assay |
The in vitro enzyme/receptor binding (cell-free) assay for β-Aminoarteether is not a typical enzyme inhibition assay, as the compound's mechanism of action is primarily immunomodulatory rather than enzyme inhibition. The compound's activity is typically assessed in cell-based assays measuring cytokine production, immune cell activation, or autoantibody production.
|
| Cell Assay |
In vitro cellular assays for β-Aminoarteether are performed using immune cells such as macrophages, T cells, or B cells. Cells are treated with varying concentrations of the compound, and inflammatory cytokine production (e.g., TNF-α, IL-6, IL-1β) is measured by ELISA. T cell proliferation and activation are assessed by flow cytometry. In autoimmune disease models, the compound's ability to inhibit autoantibody production by B cells can also be evaluated.
|
| Animal Protocol |
Animal/Disease Models: Female NZB/W F1 mice (Six and half months old)[1]
Doses: 1 mg/kg, 3 mg/kg, and 10 mg/kg Route of Administration: Oral administration; daliy; for 3 months Experimental Results: Dramatically delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice. In vivo animal experiments for β-Aminoarteether are conducted in rodent models of autoimmune diseases, such as lupus-prone MRL/lpr mice or NZB/W F1 mice. The compound is administered orally at various dose levels. Pharmacodynamic endpoints include the measurement of autoantibody levels (anti-dsDNA antibodies), assessment of proteinuria and kidney function, histopathological evaluation of kidney and other organ damage, and measurement of inflammatory cytokine levels in serum or tissues. |
| ADME/Pharmacokinetics |
β-Aminoarteether (SM934 free base) is an orally active artemisinin derivative, suggesting good oral bioavailability. As a small molecule with a molecular weight of 327.42 g/mol and a molecular formula of C17H29NO5, the compound is expected to have favorable absorption and distribution properties. However, detailed pharmacokinetic parameters such as half-life, Cmax, AUC, and clearance have not been extensively reported.
|
| Toxicity/Toxicokinetics |
Toxicology data for β-Aminoarteether are limited. The compound is an artemisinin derivative, and artemisinin-based compounds have been extensively used as antimalarial drugs with established safety profiles. However, the specific safety profile of β-Aminoarteether has not been extensively reported. The compound is used for research purposes only and is not approved for human use.
|
| References |
|
| Additional Infomation |
β-Aminoartemisinin is a derivative of artemisinin in which the (+)-artemisinin lactone is converted into the corresponding 2-aminoethyl ether lactone (the new stereocenter is in the β(S) configuration). It is an artemisinin derivative and also a primary amino compound.
β-Aminoarteether (CAS: 133162-24-0) has a molecular formula of C17H29NO5 and a molecular weight of 327.42. It is also known as SM934 free base. β-Aminoarteether is an orally active artemisinin derivative used for inflammation and autoimmune disease research, such as lupus diseases. The compound is not approved for human use and is intended for research purposes only. |
| Molecular Formula |
C17H29NO5
|
|---|---|
| Molecular Weight |
327.42
|
| Exact Mass |
327.204
|
| CAS # |
133162-24-0
|
| PubChem CID |
10019350
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OCCN)C
|
| InChi Key |
HPGHCIXRRLNXRN-XQLAAWPRSA-N
|
| InChi Code |
InChI=1S/C17H29NO5/c1-10-4-5-13-11(2)14(19-9-8-18)20-15-17(13)12(10)6-7-16(3,21-15)22-23-17/h10-15H,4-9,18H2,1-3H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
|
| Chemical Name |
2-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0542 mL | 15.2709 mL | 30.5418 mL | |
| 5 mM | 0.6108 mL | 3.0542 mL | 6.1084 mL | |
| 10 mM | 0.3054 mL | 1.5271 mL | 3.0542 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
